Print

Print


Public Funding Impacts Progress of Embryonic Stem Cell Research
Libraries
Science News Keywords
STEM CELL, EMBRYO, CLONING


Bolstered by supportive policies and public research dollars, the United 
Kingdom, Israel, China, Singapore and Australia are producing unusually 
large shares of human embryonic stem cell research. While states like 
California and New York are picking up more research funding in the U.S.

Newswise - Bolstered by supportive policies and public research dollars, the 
United Kingdom, Israel, China, Singapore and Australia are producing 
unusually large shares of human embryonic stem cell research, according to a 
report from the Georgia Institute of Technology in the June 2008 issue Cell 
Stem Cell. Aaron Levine, assistant professor of public policy and author of 
the book Cloning: A Beginner's Guide, studied how countries output of 
research papers related to human embryonic stem cell research compared to 
their output in less contentious fields. He found that even though the 
United States still puts out far more research in this field than any other 
single country, when one compares the amount of research in human embryonic 
stem cells to other forms of research in molecular biology and genetics, the 
U.S. lags behind.

"The U.S. is still the largest producer of research in this field, but 
compared to other similar fields, our share is smaller," said Levine, 
assistant professor in Georgia Tech's Ivan Allen College of Liberal Arts. 
"You have to ask yourself, are we happy producing this relatively small 
share?"

In comparison, the study showed that the U.K. and Israel were producing 
substantially more research in this area than in other fields. According to 
the study, the U.K. produced 5.3 percent more research related to human 
embryonic stem cells than research performed in other areas of molecular 
biology and genetics, while Israel produced 4.6 percent more research. 
Levine attributed that to the long-held public and political support of 
human embryonic stem cell research in those countries.

"Both the U.K. and Israel have long-standing policies that support research 
in this field," said Levine, "And this support seems likely to have 
bolstered scientists' efforts to set up labs and acquire funding for their 
research."

But the biggest surprise was China and Singapore, with China producing 3.2 
percent more human embryonic stem cell research than other areas of 
molecular biology and genetics, and Singapore producing 2.6 percent more 
research.

"China and Singapore both showed impressive performance in human embryonic 
stem cell research," said Levine. "Although these countries are very 
different, both have been striving to grow their biomedical research 
communities and it seems likely they focused on human embryonic stem cell 
research, in part, because they saw that traditional scientific powerhouses 
like the United States were moving so tentatively in this area."

Australia had a more mixed policy and a more mixed result. While Australia 
does allow new stem cell lines to be created from fertility treatments, it 
explicitly banned the use of stem cells derived from somatic cell nuclear 
transfer from 2002 to 2006. Beginning in 2006 scientists were allowed to use 
stem cells from somatic cell nuclear transfer, but under strict regulatory 
guidelines. That may explain why Levine's study found that Australia showed 
a more modest result of producing only 1.6 percent more human embryonic stem 
cell research than other areas of molecular biology and genetics.

The United States, however, is significantly under-performing in this area. 
Although Levine's study found that the U.S. produced 36 percent of the 
research performed on human embryonic stem cells, far more than any other 
country, when he compared those studies to other areas of research in 
molecular biology and genetics, he found that the U.S. had a deficit of 10 
percent.

Although the U.S. government is the funding source for 63 percent of 
academic research and development, federal funds can only be used for 
studies on a small number of stem cell lines produced before August 9, 2001. 
As a result, much research in this area in the U.S. is done either with 
state money or private money.

Given that scientists have less incentive in the private sector to publish 
research papers, it's possible that Levine's metric undercounts the amount 
of research done in this area in the U.S. But even so, the contribution from 
the U.S. is still reduced since research that isn't published does little to 
increase public knowledge.

But that may change. Venturing where the federal government fears to tread, 
states like California, New York, Connecticut and Maryland are becoming 
places researchers can turn to for human embryonic stem cell funding. But 
Levine thinks that development may complicate matters.

"There are a variety of funding sources out there now, but it makes the 
field more complicated for scientists to follow the various rules set forth 
by the states and foundations," said Levine. "I think scientists would 
prefer clear oversight from a federal government that's supportive of their 
research."

Levine plans to follow up this current work with a look at how collaboration 
is affected by these different state policies.

© 2008 Newswise.  All Rights Reserved.

Rayilyn Brown
Board Member AZNPF
Arizona Chapter National Parkinson Foundation
[log in to unmask] 

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn